Skip to main content

Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing

Written by Customer Service on . Posted in Public Companies.

DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report. This report provides an in-depth analysis of drug trends within educational institutions, shedding light on the growing challenges schools face in maintaining a drug-free environment for students and staff.

Following the success of our inaugural Workforce Insights Report earlier this year, we continue our commitment to providing groundbreaking insights based on data from hair testing. For the Education Insights Report, Psychemedics analyzed thousands of hair samples collected from students and staff in educational settings across the United States. The data offer valuable perspectives on drug use trends over the past five years, supporting schools in their efforts to combat substance abuse.

The 2024 Education Insights Report reveals key findings, including:

  • Rising Drug Positivity Rates: The overall positivity rate for drug tests in the education sector has increased by 25%, rising from 3.9% to 4.9% over the last five years.
  • Top Drugs Detected: Marijuana, nicotine, amphetamines, and cocaine were among the most commonly detected substances. Marijuana was present in 57.6% of positive tests, with nicotine following at 17.9%.
  • Emerging Delta-8 Trend: National data reveals that 11% of 12th-grade students used Delta-8 THC in the past year, a new and less understood substance gaining popularity among teens.
  • Challenges of Legalization: As marijuana legalization expands across states, schools are facing increased challenges in preventing underage access. The report highlights the importance of health and wellness-focused drug testing programs to create safer learning environments.

“Our Education Insights Report marks a pivotal moment for Psychemedics as we expand our focus to address the growing concerns of substance abuse within schools and universities,” said Brian Hullinger, Chief Executive Officer at Psychemedics. “By leveraging our innovative hair testing solutions, we aim to provide educational institutions with the tools they need to effectively monitor and address drug use, ensuring the safety and well-being of both students and staff.”

The report underscores the growing importance of drug testing within educational settings, as schools across the nation work to maintain safe and healthy environments. With hair testing offering long detection windows and unmatched accuracy, Psychemedics is at the forefront of helping schools manage these critical challenges.

To access the full Education Insights Report and learn more about Psychemedics’ hair testing solutions for educational institutions, visit https://www.psychemedics.com/whitepaper/.

For more information about Psychemedics Corporation and its innovative hair testing solutions, please visit https://www.psychemedics.com.

About Psychemedics

Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.

Investor Relations:
Phone: 978-206-8220
Email: InvestorRelations@psychemedics.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.